Pfizer Strengthens Foundation For A Long-Term COVID Commercial Business
Preparing for the eventual transition to an open commercial market for COVID-19 vaccines and treatments, Pfizer restructured its commercial team to incorporate the franchises.
You may also be interested in...
The announcement comes amid signs of lagging bivalent booster uptake despite the possibility of a fall and winter surge. Novavax announced data from its combination coronavirus-influenza vaccine, but doubts remain as its approach’s competitiveness against mRNA vaccines. Moderna and Pfizer received EUAs for their bivalent vaccines in young children.
Top-line Phase III results for Talzenna/Xtandi showed improved PFS in mCRPC patients regardless of HRR mutation status, where AstraZeneca/Merck have developed fellow PARP inhibitor Lynparza.
Moderna is seeking financial compensation for Comirnaty in its patent infringement suit, but it seems especially keen to assert IP rights over what could become an even more valuable platform technology.